MA48870B1 - Anticorps anti-sortiline et leurs méthodes d'utilisation - Google Patents

Anticorps anti-sortiline et leurs méthodes d'utilisation

Info

Publication number
MA48870B1
MA48870B1 MA48870A MA48870A MA48870B1 MA 48870 B1 MA48870 B1 MA 48870B1 MA 48870 A MA48870 A MA 48870A MA 48870 A MA48870 A MA 48870A MA 48870 B1 MA48870 B1 MA 48870B1
Authority
MA
Morocco
Prior art keywords
methods
sortlin
compositions
sortilin antibodies
antibodies
Prior art date
Application number
MA48870A
Other languages
English (en)
Other versions
MA48870A (fr
Inventor
Arnon Rosenthal
Robert Pejchal
Tina Schwabe
Michael Kurnellas
Anthony B Cooper
Original Assignee
Alector Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alector Llc filed Critical Alector Llc
Priority claimed from PCT/US2019/041614 external-priority patent/WO2020014617A1/fr
Publication of MA48870A publication Critical patent/MA48870A/fr
Publication of MA48870B1 publication Critical patent/MA48870B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne d'une manière générale des compositions qui comprennent des anticorps, par exemple des anticorps monoclonaux, chimériques, à maturation d'affinité, humanisés, des fragments d'anticorps, etc., qui se lient spécifiquement à une protéine sortiline, par exemple une sortiline humaine ou une sortiline de mammifère, et qui présentent des caractéristiques fonctionnelles améliorées et/ou accrues, et l'utilisation de telles compositions dans la prévention, la réduction des risques, ou le traitement d'un individu qui en a besoin.
MA48870A 2018-07-13 2019-07-12 Anticorps anti-sortiline et leurs méthodes d'utilisation MA48870B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862698007P 2018-07-13 2018-07-13
PCT/US2019/041614 WO2020014617A1 (fr) 2018-07-13 2019-07-12 Anticorps anti-sortiline et leurs méthodes d'utilisation

Publications (2)

Publication Number Publication Date
MA48870A MA48870A (fr) 2020-04-01
MA48870B1 true MA48870B1 (fr) 2023-03-31

Family

ID=83218695

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48870A MA48870B1 (fr) 2018-07-13 2019-07-12 Anticorps anti-sortiline et leurs méthodes d'utilisation

Country Status (2)

Country Link
AR (1) AR122237A1 (fr)
MA (1) MA48870B1 (fr)

Also Published As

Publication number Publication date
AR122237A1 (es) 2022-08-31
MA48870A (fr) 2020-04-01

Similar Documents

Publication Publication Date Title
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
MA33387B1 (fr) Polypeptides et procede de traitement
MA71118B1 (fr) Anticorps anti-c5 et leurs utilisations
MA35345B1 (fr) Proteines de liaisons a un antigene ayant une liaison accrue a fcrn
CA3156451A1 (fr) Anticorps ayant une specificite pour la nectine -4 et leurs utilisations
MA54975B1 (fr) Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
TNSN04078A1 (fr) Antibodies to cd40
MA35174B1 (fr) Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
MA29374B1 (fr) Anticorps anti-ccr5 et leurs utilisations
MA40041A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA39061A1 (fr) Modulateurs d'aplnr et leurs utilisations
MA30876B1 (fr) Anticorps de la lymphotoxine-alpha
MA42935B1 (fr) Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
MA58293B1 (fr) Molécules de liaison pd-1 et leurs procédés d'utilisation
MA34527B1 (fr) Anticorps contre la metalloproteinase de matrice 9
MA40913A (fr) Conjugués anticorps-médicament
MA35620B1 (fr) Compositions pour le traitement de l'arthrite rhumatoïde et procédés d'utilisation desdites compositions
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
MA38161A1 (fr) Anticorps anti-bmp-6
MA69688B1 (fr) Anticorps monoclonaux anti-gprc5d et leurs utilisations
MX2023010764A (es) Anticuerpo anti componente del complemento 1s (c1s).
MA53186A1 (fr) Anticorps monoclonal qui se lie spécifiquement à cd20
MA48241A1 (fr) Anticorps dirigés contre madcam